Christopher Benecchi serves as Executive at Sage Therapeutics, Inc., where they oversee executive responsibilities. Since joining the company, Christopher Benecchi has executed 7 insider transactions totaling $0, demonstrating a balanced approach to their equity position. Their most recent transaction on Jul 31, 2025 involved selling 36,375 shares valued at $0.
Christopher Benecchi currently holds 23,242 shares of Sage Therapeutics, Inc. (SAGE), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Christopher Benecchi has been a net neutral trader of SAGE stock. They have purchased $0 and sold $0 worth of shares.
Christopher Benecchi's most recent insider trade was on Jul 31, 2025, when they sold 36,375 shares at $0.00 per share.
Get notified when new Form 4 filings are submitted
| $N/A |
| Discretionary |
| Aug 5, 2024 | SAGE | $0 | Award | 16,200 | $N/A | Discretionary |
| Aug 5, 2024 | SAGE | $42.6K | Payment | 4,755 | $8.96 | Discretionary |
| Feb 13, 2024 | SAGE | $0 | Award | 13,500 | $N/A | Discretionary |
| Feb 3, 2023 | SAGE | $0 | Award | 6,750 | $N/A | Discretionary |
| Feb 3, 2023 | SAGE | $93.6K | Payment | 2,119 | $44.16 | Discretionary |